



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	Ms_JCTI_35052
Title of the Manuscript:	Dp103 in Egyptian Patients with Breast Cancer: Prognosis to Lymph Node Metastasis
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	The aim of the study is original for showing breast cancer prognostic biomarker. I did not found any ELISA kit for detecting Dp103 level in human serum samples in our survey of internet. Please give the exact kit manufacturer name of ELISA kit or internet address of Dp103 protein Moreover, if they show the protein expression levels of Dp103, MMP-9 and NF-kb in fresh tissue samples it will be more reliable for this study	The kit was specifically manufactured for this study by ELISAKitassay.com, Damastown Dublin 15, Ireland Email: info@elisakitassays.com Web: www.elisakitassays.com With Catalogue Code: ELISAHu005596. For protein expression for parameters included would be of course positive step, but we thought that measuring serum parameter (Dp 103) as marker predictor for metastasis and hence response to chemotherapy in future would be easily and less time consuming.
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		